Stock data
| Market cap. | NIS60.1m |
| Last close | NIS0.35 |
| High / Low (52 weeks) | NIS0.6 / NIS0.3 |
| Stock market listing | US, Tel Aviv Stock Exchange |
| Forecast net cash (NISm) | 5 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | (27.3) | (36.2) | (18.8) |
| Relative * | (26.5) | (33) | (30.7) |
* % Relative to local index
Other companies in sector Show
Company news
CollPlant opens Rehovot rhCollagen production plantMon, 23 Apr 2018 14:48:45 GMT |
Collplant Holdings Ltd. ADRMon, 02 Oct 2017 09:21:16 GMT |
BRIEF-Collplant Petitions Court To Voluntarily Delist Ordinary Shares From The ...Mon, 16 Apr 2018 10:41:15 GMT |
Regenerative medicine co CollPlant raises $7.4mSun, 12 Nov 2017 16:08:28 GMT |
CollPlant files to raise $25m on Wall StreetTue, 25 Oct 2016 09:45:00 GMT |
| Y/E Dec | Revenue (NISm) | EBITDA (NISm) | PBT (NISm) | EPS (NIS) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 0.3 | (27.0) | (27.9) | (27.72) | N/A | N/A |
| 2017A | 1.7 | (19.7) | (20.9) | (15.68) | N/A | N/A |
| 2018E | 3.2 | (17.8) | (18.8) | (10.46) | N/A | N/A |
| 2019E | 7.1 | (16.9) | (18.3) | (9.69) | N/A | N/A |
Last updated on 29/03/2018
Latest research
Big potential for BioInk
Update | Pharmaceutical & healthcare | 28/03/2018
Steady commercial advancement
Update | Pharmaceutical & healthcare | 04/12/2017
Fund-raising should enable strategic delivery
Update | Pharmaceutical & healthcare | 18/09/2017
Continuing to build on 2016
Update | Pharmaceutical & healthcare | 05/06/2017
Good progress in 2016
Update | Pharmaceutical & healthcare | 04/04/2017
Solid foundations with potential for growth
Initiation | Pharmaceutical & healthcare | 09/03/2017
המחקר העדכני ביותר
קולפלנט אחזקות
BioInk- פוטנציאל גדול ל
28/03/2018
קולפלנט אחזקות
התקדמות מסחרית עיקבית
04/12/2017
קולפלנט אחזקות
קולפלנט אחזקות
05/06/2017
Investment summary
Over the course of H217, CollPlant announced that it had received orders for its BioInk product from two companies for development of 3D printed organs and orthopaedic devices respectively. In the FY17 results the company announced that the first two orders accounted for NIS0.69m in revenue, bringing revenue for the year to NIS1.67m. One of the clients placed a repeat order, which is expected to be recorded in Q118 results.
Last updated on 28/03/2018
Industry outlook
Orthobiologics and advanced wound care are substantial growing markets and are estimated to be worth $6.7bn (according to GlobalData) and $8.5bn (according to Smith & Nephew) respectively.
Last updated on 02/03/2018
Key management
| Yehiel Tal, CEO |
| Eran Rotem, CFO |
Company address
| 3 Sapir Street Weizmann Science Park, P.o.B 4132 Ness-Ziona Nes Ziona 74140 Israel 972-73-232-5600 View website |